Aluminium in Allergies and Allergen immunotherapy

World Allergy Organization Journal

Volumn 8, Issue 1, 2015, Pages

  Jensen Jarolim, Erika ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant; Allergen; Allergen immunotherapy; Aluminium; Th2

Indexed keywords

ALLERGEN; ALUMINUM; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ANTHRAX VACCINE; BACTERIAL VACCINE; CHICKENPOX VACCINE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; FERRITIN; GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; INTERLEUKIN 10; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; POTASSIUM SALT; RABIES VACCINE; RUBELLA VACCINE; TRANSFORMING GROWTH FACTOR BETA; VIRUS VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ALLERGIC REACTION; ALLERGY; ANTHRAX; ARTICLE; AUTOIMMUNE DISEASE; AVIAN INFECTIOUS BRONCHITIS VIRUS; BORDETELLA BRONCHISEPTICA; CANINE ADENOVIRUS 1; CHICKENPOX; CLOSTRIDIA; DIPHTHERIA; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; FOOD ALLERGY; FOOT AND MOUTH DISEASE; HAEMOPHILUS INFECTION; HEPATITIS A; HEPATITIS B; IMMUNOTHERAPY; INFLUENZA; INNATE IMMUNITY; LEPTOSPIRA INTERROGANS; MASS SPECTROMETRY; MUMPS; NEWCASTLE DISEASE VIRUS; NONHUMAN; PAPILLOMA; PASTEURELLA MULTOCIDA; PERTUSSIS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRECIPITATION; PRIORITY JOURNAL; RABIES; RUBELLA; SYSTEMIC ALLERGEN IMMUNOTHERAPY; TETANUS; TH1 CELL; TH2 CELL; VACCINATION;

EID: 84928750939     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/s40413-015-0060-5     Document Type: Article

References (78)

1. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes XVLL.-XXIV. J Pathol Bacteriol. 1926;29:31-40. doi:10.1002/Path.1700290106.
2. Bousfield G. Clinical trials of diphtheria toxoid aluminium-phosphate-precipitated; to determine optional aluminium-phosphate content. Lancet. 1947;1:286-8.
3. Mc Comb J, Trafton MZ. Immune responses and reactions to diphtheria and tetanus toxoids, with pertussis vaccine, aluminum phosphate precipitated. N Engl J Med. 1950;243:442-4. doi:10.1056/NEJM195009212431204.
4. Baylor NW, Egan W, Richman P. Aluminum salts in vaccines-US perspective. Vaccine. 2002;20 Suppl 3:S18-23.
5. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004;82:497-505. doi:10.1111/j.0818-9641.2004.01286.x.
6. Hussels F. [Eight to twelve month follow-up of the results of rapid treatment of syphilis with PAM, procaine penicillin G in oil with aluminum monostearate]. Therapie der Gegenwart. 1950;89:332-6.
7. Bohls SW, Cook EB, Potter RT. Oral and parenteral use of aluminum penicillin mixtures in the treatment of gonorrhea. J Vener Dis Inf. 1946;27:69-74.
8. Hirsh HL, Kurland W. The treatment of various infections with single doses of 300,000 units of procaine penicillin in oil plus aluminum monostearate. Am Pract Dig Treat. 1950;1:923-5.
9. McIntosh JF, Sutherland CG. The Use of Colloidal Aluminium Hydroxide in the Treatment of Peptic Ulcer. Can Med Assoc J. 1940;42:140-5.
10. Rossien AX, Stanton A, Feuerstein SS. An evaluation of the antacid activity of a "special" aluminum hydroxide mixture. Rev Gastroenterol. 1951;18:535-9.
11. Friedman MH. Aluminum hydroxide gel for erosions in patients with bowel fistulas. JAMA. 1946;131:520-2.
12. Clark BB, Adams WL. The effect of gastric antacids on gastric secretion as observed in the Cope pouch dog; sodium bicarbonate, aluminum hydroxide gel, calcium carbonate, magnesium oxide, and sodium citrate. Gastroenterology. 1947;9:284-92.
13. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009;8:645-60. doi:10.1038/nrd2653.
14. Soyka MB, Holzmann D, Akdis CA. Regulatory cells in allergen-specific immunotherapy. Immunotherapy. 2012;4:389-96. doi:10.2217/imt.12.10.
15. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8:218-30. doi:10.1038/nri2262.
16. Jarolim E, Poulsen LK, Stadler BM, Mosbech H, Oesterballe O, Kraft D, et al. A long-term follow-up study of hyposensitization with immunoblotting. J Allergy Clin Immunol. 1990;85:996-1004.
17. Freeman J. Further observations on the treatment of Hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911;2:814-7.
18. Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;1:1572-3.
19. Zoss A, Koch C, Hirose R. Alum-ragweed precipitate: preparation and clinical investigation; preliminary. J Allergy. 1937;8:329.
20. Naterman HL. Pollen tannate suspended in peanut oil with aluminum monostearate in the treatment of hay fever. J Allergy. 1951;22:175-82.
21. Holzman RS, Norman PS. The effect of alum concentration on the repository and adjuvant properties of alum-precipitated antigens. J Allergy. 1966;38:65-73.
22. Moingeon P. Adjuvants for allergy vaccines. Hum Vaccines Immunother. 2012;8:1492-8. doi:10.4161/hv.21688.
23. Levine BB, Vaz NM. Effect of combinations of inbred strain, antigen, and antigen dose on immune responsiveness and reagin production in the mouse. A potential mouse model for immune aspects of human atopic allergy. Int Arch Allergy Appl Immunol. 1970;39:156-71.
24. Revoltella R, Ovary Z. Preferential production of rabbit reaginic antibodies. Int Arch Allergy Appl Immunol. 1969;36:282-9.
25. Revoltella R, Ovary Z. Reaginic antibody production in different mouse strains. Immunology. 1969;17:45-54.
26. Black L. The adjuvant activity of saponin and aluminium hydroxide for promoting reagins. J Immunol Methods. 1977;15:193-5.
27. Lehrer SB, Vaughn JH, Tan EM. Enhancement of reaginic and hemagglutinating antibody production by an extract of Bordetella pertussis containing histamine sensitizing factor. J Immunol. 1976;116:178-83.
28. Pauwels R, Van der Straeten M, Platteau B, Bazin H. The non-specific enhancement of allergy. I. In vivo effects of Bordetella pertussis vaccine on IgE synthesis. Allergy. 1983;38:239-46.
29. Marsh DG, Lichtenstein LM, Norman PS. Induction of IgE-mediated immediate hypersensitivity to group I rye grass pollen allergen and allergoids in non-allergic man. Immunology. 1972;22:1013-28.
30. Kepron W, James JM, Kirk B, Sehon AH, Tse KS. A canine model for reaginic hypersensitivity and allergic bronchoconstriction. J Allergy Clin Immunol. 1977;59:64-9.
31. Black L. Allergy in cattle after foot-and-mouth disease vaccination. Vet Rec. 1977;100:195-8.
32. Itaya T, Tomioka H, Kumagai A, Tada T. Suppression of IgE antibody formation in mice with nonspecific stimulation. Int Arch Allergy Appl Immunol. 1980;62:389-96.
33. Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, et al. A. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine. 1997;15:1314-8.
34. Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett. 2010;128:29-35. doi:10.4161/hv.21688.
35. Moingeon P, Mascarell L. Novel routes for allergen immunotherapy: safety, efficacy and mode of action. Immunotherapy 2012;4(2):201-212. doi:10.2217/Imt.11.171.
36. Ekramoddoullah AK, Kisil FT, Sehon AH. Suppression of the IgE antibody response in mice to kentucky blue grass pollen allergens. Int Arch Allergy Appl Immunol. 1977;55:247-54.
37. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol. 2003;112:915-22. doi:10.1016/S0091.
38. Hantusch B, Scholl I, Harwanegg C, Krieger S, Becker WM, Spitzauer S, et al. Affinity determinations of purified IgE and IgG antibodies against the major pollen allergens Phl p 5a and Bet v 1a: discrepancy between IgE and IgG binding strength. Immunol Lett. 2005;97:81-9. doi:10.1016/j.imlet.2004.10.002.
39. Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2012;3:406. doi:10.3389/fimmu.2012.00406.
40. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287-93. doi:10.1038/nri2510.
41. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol. 2009;183:4403-14. doi:10.4049/jimmunol.0900164.
42. Kuroda E, Coban C, Ishii KJ. Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol. 2013;32:209-20. doi:10.3109/08830185.2013.773326.
43. Pollock KG, Conacher M, Wei XQ, Alexander J, Brewer JM. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology. 2003;108:137-43.
44. Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31:103-9. doi:10.1016/J.It.2009.12.009
45. Sun H, Pollock KG, Brewer JM. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine. 2003;21:849-55.
46. Manzano-Szalai K, Thell K, Willensdorfer A, Weghofer M, Pfanzagl B, Singer J, et al. Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c mice. Viral Immunol. 2014. doi:10.1089/vim.2014.0059.
47. Hebert J, Small P. Comparison of alum-precipitated aqueous extracts and modified ragweed tyrosine adsorbate vaccine in the treatment of ragweed hay fever. Ann Allergy. 1988;60:226-30.
48. Boye NP, Salo OP, Hyldebrandt N, Wihl JA, Bevan A, Harris RI, et al. Immunotherapy of tree pollen allergy with a modified alginate conjugated birch pollen extract compared to an aluminium adsorbed extract. Allergy. 1990;45:241-8.
49. Scholl I, Boltz-Nitulescu G, Jensen-Jarolim E. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Control Release. 2005;104:1-27. doi:10.1016/j.jconrel.2004.12.020.
50. Pali-Scholl I, Szollosi H, Starkl P, Scheicher B, Stremnitzer C, Hofmeister A, et al. Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm. 2013;85:656-64. doi:10.1016/J.Ejpb.2013.03.003
51. Roth-Walter F, Scholl I, Untersmayr E, Fuchs R, Boltz-Nitulescu G, Weissenbock A, et al. M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J Allergy Clin Immunol. 2004;114:1362-8. doi:10.1016/j.jaci.2004.08.010.
52. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61:927-34. doi:10.1099/jmm. 0.038943-0.
53. Exley C. Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy. Allergy, Asthma, and Clinical Immunology: official journal of the Canadian Society of Allergy and. Clin Immunol. 2014;10:4. doi:10.1186/1710-1492-10-4.
54. Garcia-Patos V, Pujol RM, Alomar A, Cistero A, Curell R, Fernandez-Figueras MT, et al. Persistent subcutaneous nodules in patients hyposensitized with aluminum-containing allergen extracts. Arch Dermatol. 1995;131:1421-4.
55. Heidary N, Cohen DE. Hypersensitivity reactions to vaccine components. Dermatitis: contact, atopic, occupational, drug. 2005;16:115-20.
56. Osterballe O. Side effects during immunotherapy with purified grass pollen extracts. Allergy. 1982;37:553-62.
57. Netterlid E, Hindsen M, Siemund I, Bjork J, Werner S, Jacobsson H, et al. Does allergen-specific immunotherapy induce contact allergy to aluminium? Acta Derm Venereol. 2013;93:50-6. doi:10.2340/00015555-1409.
58. Exley C. Human exposure to aluminium. Environ Sci Processes Impacts. 2013;15:1807-16. doi:10.1039/c3em00374d.
59. Martyn CN, Barker DJ, Osmond C, Harris EC, Edwardson JA, Lacey RF. Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet. 1989;1:59-62.
60. World Health Organizaion. Aluminium. Geneva, WHO International Programme on Chemical Safety (Environmental Health Criteria 194). 1997.
61. European Food Safety Authority, EFSA. Technical report: Dietary exposure to aluminium-containing food additives. http://www.efsa.europa.eu/en/supporting/pub/411e.htm. March 2013.;Parma, Italy:Supporting Publications 2013:EN-411.
62. Roth LE, Dunlap JR, Stacey G. Localizations of Aluminum in Soybean Bacteroids and Seeds. Appl Environ Microb. 1987;53:2548-53.
63. Food and Drug Administration, Dept. of Health and Human Services. 21. Food and Drugs. Biologics: General Biological Product Standards. 21CFR61015. 1 April 2014; 7: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.15.
64. Vaccine-Education-Center. Do vaccines contain aluminum? Reviewed by Offit, PA. http://vec.chop.edu/service/vaccine-education-center/vaccine-safety/vaccine-ingredients/aluminum.html. March 2014.
65. Willhite CC, Karyakina NA, Yokel RA, Yenugadhati N, Wisniewski TM, Arnold IM, et al. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol. 2014;44 Suppl 4:1-80. doi:10.3109/10408444.2014.934439.
66. Banasik A, Lankoff A, Piskulak A, Adamowska K, Lisowska H, Wojcik A. Aluminum-induced micronuclei and apoptosis in human peripheral-blood lymphocytes treated during different phases of the cell cycle. Environ Toxicol. 2005;20:402-6. doi:10.1002/tox.20125.
67. Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012;21:223-30. doi:10.1177/0961203311430221.
68. Schwarz MJ. Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms. Dialogues Clin Neurosci. 2003;5:139-53.
69. Khan Z, Combadiere C, Authier FJ, Itier V, Lux F, Exley C, et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med. 2013;11:99. doi:10.1186/1741-7015-11-99.
70. De Sole P, Rossi C, Chiarpotto M, Ciasca G, Bocca B, Alimonti A, et al. Possible relationship between Al/ferritin complex and Alzheimer's disease. Clin Biochem. 2013;46:89-93. doi:10.1016/j.clinbiochem.2012.10.023.
71. Mold M, Eriksson H, Siesjo P, Darabi A, Shardlow E, Exley C. Unequivocal identification of intracellular aluminium adjuvant in a monocytic THP-1 cell line. Sci Rep. 2014;4:6287. doi:10.1038/srep06287.
72. Brunner R, Wallmann J, Szalai K, Karagiannis P, Altmeppen H, Riemer AB, et al. Aluminium per se and in the anti-acid drug sucralfate promotes sensitization via the oral route. Allergy. 2009;64:890-7.
73. Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, et al. The impact of aluminium in acid-suppressing drugs on the immune response of BALB/c mice. Clin Exp Allergy. 2007;37:1566-73. doi:10.1111/j.1365-2222.2007.02813.x.
74. Rosenblum H, Shoenfeld Y, Amital H. The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am. 2011;25:851-63. doi:10.1016/j.idc.2011.07.012.
75. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 2013;47:1-16. doi:10.1016/j.jaut.2013.10.004.
76. Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: Who might be at risk? Pharmacol Res. Epub 2014/10/04. doi:10.1016/j.phrs.2014.08.002.
77. Commission of the French Parliament. 2/7 Colloque de L'OPECST sur les effets secondaires d'adjuvants vaccinaux. YouTube. 22 May 2014; https://www.youtube.com/watch?v=zmpKMGGiJpg&feature=youtu.be.
78. Greßler S, Fries R. Aluminium. Toxikologie und gesundheitliche Aspekte bei körpernahen Anwendungen. Publisher: Austrian Ministry of Health, (editor Herzog, U). http://www.bmg.gv.at/cms/home/attachments/3/9/6/CH1146/CMS1402477436830/aluminium-studie-2014.pdf. June 2014.